about
Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspectivePersonalized therapy for lung cancer: Striking a moving targetCombining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
EGFR G796D mutation mediates resistance to osimertinib.
@en
type
label
EGFR G796D mutation mediates resistance to osimertinib.
@en
prefLabel
EGFR G796D mutation mediates resistance to osimertinib.
@en
P2093
P2860
P356
P1433
P1476
EGFR G796D mutation mediates resistance to osimertinib.
@en
P2093
Chunyan Wu
Jianfang Xu
Jiying Wang
Xuehua Zhu
Xuesong Lu
P2860
P304
49671-49679
P356
10.18632/ONCOTARGET.17913
P407
P577
2017-05-16T00:00:00Z